APOB and COVID-19: In the OL 100 mg resmetirom arm, the reductions from baseline in LDL-C, −19.4% (2.6%), apoB, −21.3% (2.1%) and TG, −27.5% (4.5%) at week 24 were numerically greater than those achieved in the DB resmetirom arms (potentially due to more missed doses of study drug in the DB arms as a result of COVID-19-related drug kit delays).